Tudor Investment Corp ET AL Purchases New Position in Tilray Brands, Inc. $TLRY

Tudor Investment Corp ET AL acquired a new stake in Tilray Brands, Inc. (NASDAQ:TLRY) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 299,398 shares of the company’s stock, valued at approximately $518,000. Tudor Investment Corp ET AL owned 0.27% of Tilray Brands at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in TLRY. Oppenheimer & Co. Inc. acquired a new position in Tilray Brands during the 3rd quarter worth approximately $25,000. Silverlake Wealth Management LLC acquired a new position in shares of Tilray Brands in the third quarter worth $25,000. Unified Investment Management purchased a new position in Tilray Brands in the 3rd quarter valued at about $26,000. Y Intercept Hong Kong Ltd purchased a new position in shares of Tilray Brands during the third quarter valued at approximately $30,000. Finally, HighPoint Advisor Group LLC purchased a new position in shares of Tilray Brands during the 3rd quarter worth $33,000. Hedge funds and other institutional investors own 9.35% of the company’s stock.

Tilray Brands Price Performance

NASDAQ TLRY opened at $6.14 on Thursday. The business’s fifty day moving average is $7.37 and its two-hundred day moving average is $10.25. The stock has a market capitalization of $715.35 million, a P/E ratio of -0.28 and a beta of 1.96. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.72 and a current ratio of 2.81. Tilray Brands, Inc. has a 1 year low of $3.51 and a 1 year high of $23.20.

Tilray Brands (NASDAQ:TLRY) last posted its quarterly earnings data on Thursday, January 8th. The company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.12. The firm had revenue of $217.51 million during the quarter, compared to analyst estimates of $211.15 million. Tilray Brands had a negative net margin of 251.69% and a negative return on equity of 6.35%. During the same quarter last year, the business posted ($0.03) EPS. On average, research analysts forecast that Tilray Brands, Inc. will post -0.2 earnings per share for the current fiscal year.

More Tilray Brands News

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Record revenue and top-line beat — Tilray reported roughly $206.7–$207M in Q3 revenue (about +11% organic) and beat consensus, with gross profit rising to ~$55M, showing improvement in core sales. Tilray Brands Delivers Record Q3 Fiscal 2026 Results
• Positive Sentiment: Strong international cannabis growth — management highlighted a 73% increase in international cannabis revenue and a 100% rise in flower volume year-over-year, supporting the company’s global cannabis thesis. Tilray Brands Delivers Record Q3 Fiscal 2026 Results (Yahoo)
• Positive Sentiment: Strategic beverage and brand moves — Tilray closed the BrewDog acquisition (~£40M) and is expanding branded RTD offerings (Popsicle partnership, new Shock Top SKU), which could boost longer-term beverage scale if margins improve. Is Tilray Among the 11 Best Marijuana Stocks? (InsiderMonkey)
• Neutral Sentiment: Company reaffirmed FY26 outlook — management kept guidance intact, which removes some downside but didn’t materially exceed street expectations. Tilray Brands reaffirms outlook after record quarter
• Neutral Sentiment: Earnings call highlighted strategy and execution challenges — management discussed growth initiatives and margin work in beverages and international markets; these are strategic positives but will take time to convert to improved margins. Tilray Brands Inc Q3 2026 Earnings Call Highlights
• Negative Sentiment: Analyst downgrade and tempered expectations — TD Cowen and other firms reduced targets/expectations, weighing on sentiment and amplifying the sell-off. TD Cowen Has Lowered Expectations for Tilray Brands
• Negative Sentiment: Mixed profitability and margin pressure — despite narrower losses, some outlets flagged a Q3 EPS miss or continued GAAP losses and a deeply negative net margin, keeping investor concerns about near-term profitability elevated. Tilray Reports Q3 Loss, Beats Revenue Estimates (Zacks)
• Negative Sentiment: Immediate market reaction was negative — several market pieces explain the sell-off (profitability skepticism, beverage margin concerns, and analyst actions) despite the revenue beat. Tilray Sinks 4%: 3 Reasons the Market Isn’t Impressed (Yahoo)

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on TLRY shares. ATB Cormark Capital Markets raised shares of Tilray Brands from a “strong sell” rating to a “hold” rating in a research report on Wednesday, December 10th. TD Cowen lowered their target price on Tilray Brands from $10.00 to $7.00 and set a “buy” rating for the company in a research note on Monday. Roth Mkm dropped their price target on shares of Tilray Brands from $20.00 to $10.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 20th. Zacks Research raised Tilray Brands from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 11th. Finally, Wall Street Zen raised shares of Tilray Brands from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Two equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $11.75.

Tilray Brands Profile

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.